Orchestra BioMed Holdings, Inc. OBIO
Set alert
5.78 USD +0.09 +1.63%
As of Nov 3, 11:46 AM ET
5.66 Day range 5.98
3.46 52-week range 6.50
- YTD
- +39.34%
- 1 year
- +46.40%
- Open
- 5.70
- Prev close
- 5.69
- Mkt cap
- 347.71M
- Vol
- 26.14K
- Avg vol
- 339.03K
- EPS
- -0.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.66
- High
- 5.98
- Forward P/E
- -2.66
- Beta
- 0.41
- Short ratio
- 12.51
- Inst. own
- 54.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 5.55
- 200-d avg
- 5.90
- 1y target
- 15.60
3M chart
Signals (18)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 2026 | 2 hours ago |
| SMA: Bullish | Nov 3, 2026 | 2 hours ago |
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| MACD: Buy Signal | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| RSI: Overbought | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
Analyst view
Price target (mean) 15.60 +169.8% upside
Now 5.78
- Target (low)
- 14.00
- Target (mean)
- 15.60
- Target (high)
- 20.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.425 | -0.44 – -0.42 | -0.3209 | -32.4% | 829.60K | +216.6% | 4 |
| Next quarter | -0.45667 | -0.48 – -0.42 | -0.38 | -20.2% | 830.25K | +33.9% | 3 |
| Current year | -1.66 | -1.67 – -1.65 | -1.43 | -15.4% | 3.18M | +15.2% | 4 |
| Next year | -1.95 | -2.09 – -1.72 | -1.66 | -17.5% | 3.84M | +20.8% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 13, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Jul 25, 2024 | B. Riley Securities | Initiated | — | Buy |
| Jun 12, 2024 | Chardan Capital | Reiterated | Buy | Buy |
| Mar 28, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Jan 19, 2024 | Jefferies | Initiated | — | Buy |
| Aug 11, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| Aug 9, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| May 15, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| Feb 24, 2023 | Piper Sandler | Initiated | — | Overweight |
| Feb 7, 2023 | Chardan Capital | Initiated | — | Buy |